AMGN

#80
Amgen Inc. - Common Stock
336.7 0 USD
+0.07%
セクター: ヘルスケア
ベース: USD
利益通貨: USD
日中レンジ
335.47
337.47
1年のレンジ
267.83
391.29
1日の変化
+0.07%
月次変化
-1.19%
6か月変化
-1.90%
1年の変化
+18.83%
以前の終値
336.4 8
Open
335.4 7
安値
335.4 7
High
337.4 7
ボリューム
3 578
チャート全体を表示 Full chart

Financials

概要 明細書 統計 配当金
期次 年次
  • Market Capitalization 181.72 B
  • Employee 32 K
  • Founded 1980
  • CEO Robert A. Bradway
  • Website www.amgen.com
  • Headquarter Delaware, United States
  • FIGI BBG000BBS2Y0
  • Industry 医薬品メーカー（一般）
総売上高
当期純利益
1株当たり基本利益（基本EPS）
有利子負債合計
フリーキャッシュフロー
現金および現金同等物
株価収益率
24.49
売上高対価格比率
5.13
1株当たり配当金
2.52
配当利回り（％）
2.79

Amgen Inc. - Common Stock

Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics. The company's major products are Prolia and XGEVA for treatment of osteoporosis and bone diseases, Enbrel for treatment of autoimmune diseases, Repatha for treatment of hyperlipidemia, Otezla for treatment of psoriasis and psoriatic arthritis, Tepezza to treat Graves' ophthalmopathy, Evenity to treat osteoporosis, Kyprolis to treat cancer, Nplate to regulate platelet production, and Aranesp to stimulate erythropoiesis. Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection. The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. The company is ranked 134th on the Fortune 500 and 202nd on the Forbes Global 2000.

ニュース